Literature DB >> 24264558

A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection.

Najib M Rahman1, Brennan C Kahan2, Robert F Miller3, Fergus V Gleeson4, Andrew J Nunn2, Nicholas A Maskell5.   

Abstract

BACKGROUND: Pleural infection is associated with a high morbidity and mortality. Development of a validated clinical risk score at presentation to identify those at high risk of dying would enable patient triage and may help formulate early management strategies.
METHODS: A clinical risk score was derived based on data from patients entering the multicenter UK pleural infection trial (first Multicenter Intrapleural Sepsis Trial [MIST1], n=411). From 22 baseline clinical characteristics, model selection was undertaken to find variables predictive of poor clinical outcome. Outcomes were mortality at 3 months (primary), need for surgical intervention at 3 months, and time from randomization to discharge. The derived scoring system RAPID (renal, age, purulence, infection source, and dietary factors) was validated using patients enrolled in the subsequent MIST2 trial (n=191).
RESULTS: Age, urea, albumin, hospital-acquired infection, and nonpurulence predicted poor outcome. Patients were stratified into low-risk (0-2), medium-risk (3-4), and high-risk (5-7) groups. Using the low-risk group as a reference, a RAPID score of 3 to 4 and >4 was associated with an OR of 24.4 (95% CI, 3.1-186.7; P=.002) and 192.4 (95% CI, 25.0-1480.4; P<.001), respectively, for death at 3 months. In the validation cohort (MIST2), a medium-risk RAPID score was nonsignificantly associated with mortality (OR, 3.2; 95% CI, 0.8-13.2; P=.11), and a high-risk score was associated with increased mortality (OR, 14.1; 95% CI, 3.5-56.8; P<.001). Hospitalization duration was associated with increasing RAPID score (score 0-2: median duration=7, interquartile range 6-13; score>5: median duration=15, interquartile range 9-28, P=.08).
CONCLUSIONS: The RAPID score may permit risk stratification of patients with pleural infection at presentation.

Entities:  

Mesh:

Year:  2014        PMID: 24264558     DOI: 10.1378/chest.13-1558

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Advances and controversies in pleural diseases.

Authors:  José M Porcel; Georgios Statophoulos; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 2.  Interpreting pleural fluid results .

Authors:  Rachel M Mercer; John P Corcoran; Jose M Porcel; Najib M Rahman; Ioannis Psallidas
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

3.  Risk Stratification in Patients with Complicated Parapneumonic Effusions and Empyema Using the RAPID Score.

Authors:  Sunkaru Touray; Rahul N Sood; Daniel Lindstrom; Jonathan Holdorf; Sumera Ahmad; Daniel B Knox; Andres F Sosa
Journal:  Lung       Date:  2018-08-11       Impact factor: 2.584

Review 4.  Stage-directed therapy of pleural empyema.

Authors:  Martin Reichert; Matthias Hecker; Biruta Witte; Johannes Bodner; Winfried Padberg; Markus A Weigand; Andreas Hecker
Journal:  Langenbecks Arch Surg       Date:  2016-11-04       Impact factor: 3.445

5.  Manual Intrapleural Saline Flushing Plus Urokinase: A Potentially Useful Therapy for Complicated Parapneumonic Effusions and Empyemas.

Authors:  José M Porcel; Horacio Valencia; Silvia Bielsa
Journal:  Lung       Date:  2016-11-19       Impact factor: 2.584

6.  Making the transition from video-assisted thoracoscopic surgery to chest tube with fibrinolytics for empyema in children: Any change in outcomes?

Authors:  Michael H Livingston; Sara Colozza; Kelly N Vogt; Neil Merritt; Andreana Bütter
Journal:  Can J Surg       Date:  2016-06       Impact factor: 2.089

Review 7.  The past, current and future of diagnosis and management of pleural disease.

Authors:  Jason Akulian; David Feller-Kopman
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

8.  Electrolyzed Saline Irrigation for Elimination of Bacterial Colonization in the Empyema Space.

Authors:  Kembu Nakamoto; Motohiro Takeshige; Toshiyuki Fujii; Hiroshi Hashiyada; Kazuya Yoshida; Sadahiro Kawamoto
Journal:  Surg Infect (Larchmt)       Date:  2016-08-11       Impact factor: 2.150

Review 9.  Diagnostic approach to pleural diseases: new tricks for an old trade.

Authors:  Fabien Maldonado; Robert J Lentz; Richard W Light
Journal:  F1000Res       Date:  2017-07-17

10.  Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections.

Authors:  Jason R McClune; Candice L Wilshire; Jed A Gorden; Brian E Louie; Alexander S Farviar; Michael J Stefanski; Eric Vallieres; Ralph W Aye; Christopher R Gilbert
Journal:  Can Respir J       Date:  2016-06-30       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.